Targeting TOR dependence in cancer

Matthew R. Janes; David A. Fruman

doi:10.18632/oncotarget.110

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Targeting TOR dependence in cancer

Matthew R. Janes and David A. Fruman _

PDF | How to cite

Oncotarget. 2010; 1:69-76. https://doi.org/10.18632/oncotarget.110

Metrics: PDF 3716 views | ?

Abstract

Received: May 3, 2010, Accepted: May 5, 2010, Published: May 10, 2010

A challenge in cancer therapy has been to identify targets whose function is essential for survival of malignant cells but not normal cells. This Perspective discusses recent evidence that novel inhibitors of the kinase TOR can provide an unprecedented balance of anti-cancer efficacy and tolerability.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 110

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Targeting TOR dependence in cancer

Abstract